Tracer library / [89Zr]DFO-NY003/

[89Zr]DFO-NY003/

Also written as [Zr-89]Zr-DFO-NY003/

Radionuclide: Zr-89 t½ 4704 min
Modality: PET
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Breast cancer Preclinical only, no clinical indication yet

What it is

Compound class: DFO-conjugated anti-TROP-2 antibody
Target / mechanism: TROP-2 (trophoblast cell-surface antigen-2) PMID 38194043
Clinical application: ImmunoPET imaging and radioimmunotherapy theranostic pair for TROP-2 positive triple-negative breast cancer PMID 38194043
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
SmartModule X	custom manifold	SPE	56% not corrected	>99%	DFO-Bz-NCS-NY003	38194043 2024 EJNMMI Radiopharm Chem A self-designed radiolabelling module (SmartModule X) was employed for radiochemical synthesis. - The non-decay-corrected radiochemical yields of [89Zr]Zr-DFO-NY003 and [177Lu]Lu-DTPA-NY003 were 56% and 96%, respectively.

Need this precursor?We can point you to suppliers for [89Zr]DFO-NY003/, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38194043. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 38194043: 'Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model.'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Zr-89 is a positron emitter used only for PET imaging. Linked articles: PMID 38194043.